Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A variant of the glucose transporter gene SLC2A2 modifies the glycaemic response to metformin therapy in recently diagnosed type 2 diabetes

9 Nov 2018

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diabetes, Cardiovascular Risks, and Lipoproteins
Share to Diabetes Treatment and Management
Share to Metabolism, Diabetes, and Cancer

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 30413829
DOI: 10.1007/s00125-018-4759-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A variant of the glucose transporter gene SLC2A2 modifies the glycaemic response to metformin therapy in recently diagnosed type 2 diabetesPMID 30413829Read ↗

Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin.Semantic proximity Read ↗

Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patientsSemantic proximity Read ↗

Identification of clinical and pharmacogenetic factors influencing metformin response in Type 2 diabetes mellitus.Semantic proximity Read ↗

Impact of SLC22A1 variants rs622342 and rs72552763 on HbA1c and metformin plasmatic concentration levels in patients with type 2 diabetes mellitusSemantic proximity Read ↗

Pharmacogenetic impact of SLC22A1 gene variant rs628031 (G/A) in newly diagnosed Indian type 2 diabetes patients undergoing metformin monotherapy.Semantic proximity Read ↗

Pharmacogenetics and personalized treatment of type 2 diabetesSemantic proximity Read ↗

Implications of genetic variations, differential gene expression, and allele-specific expression on metformin response in drug-naïve type 2 diabetes.Semantic proximity Read ↗

Altered Glycemic Control Associated With Polymorphisms in the SLC22A1 (OCT1) Gene in a Mexican Population With Type 2 Diabetes Mellitus Treated With Metformin: A Cohort StudySemantic proximity Read ↗

Pharmacogenetic studies update in type 2 diabetes mellitusSemantic proximity Read ↗

The Effect of Genetic Variants of SLC22A2 (rs662301 and rs315978) on the response to Metformin in type 2 Saudi diabetic patients.Semantic proximity Read ↗

Exome Sequence Data of Eight SLC Transporters Reveal That SLC22A1 and SLC22A3 Variants Alter Metformin Pharmacokinetics and Glycemic ControlSemantic proximity Read ↗

A Review of the Impact of Pharmacogenetics and Metabolomics on the Efficacy of Metformin in Type 2 DiabetesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.